CES 2026 sold diagnosis-shaped promises. None of the headline devices is FDA-cleared

The consumer health hall at CES has always run on implication. A device measures something measurable, presents it next to a health-sounding word, and leaves the inference to the buyer. This year the inference got shorter.

Among the health products drawing attention at the Las Vegas show were a mirror that analyses blood flow patterns to score metabolic health, heart health and physiological age in 30 seconds — $899 plus a $99 annual subscription — and a handheld device claiming to detect food allergens and gluten within minutes [s1]. Samsung showed Brain Health, which analyses walking patterns and voice for signs of cognitive decline [s1]. Withings showed a scale-type device measuring ECG, arterial stiffness and metabolic efficiency in 90 seconds [s1].

None of them is described as an FDA-cleared medical device [s1]. Samsung's feature is explicitly stated as not intended to diagnose medical conditions [s1].

That disclaimer is doing an enormous amount of work.

The scale of the audience

This is not a niche category. More than 86.4 million U.S. consumers — nearly a quarter of the population — are projected to use a health-related smart wearable in 2026 [s2].

The show's award list gives a sense of where the category is heading. CES Innovation Award honourees included Derma Reader 2.0, which uses AI skin analysis to bring what its makers describe as dermatologist-level diagnostics into retail settings; a home therapy booth pairing biometric monitoring with an AI mental coach; and SleepQ, which analyses behavioural, sleep and wearable data to forecast insomnia and recommend medication timing [s2].

Read that last one twice. A consumer product forecasting a condition and making a timing recommendation about medication is describing, in plain language, a clinical function.

The regulatory line moved during the show

On 7 January, FDA Commissioner Marty Makary announced at CES that low-risk devices would receive relaxed regulatory oversight, covering heart rate monitors, general health and wellness wearables, software providing informational tracking of health metrics, and AI-enabled health and wellness devices [s3].

Makary drew the line explicitly around claims rather than capability. "We want to let companies know, with very clear guidance, that if their device or software is simply providing information, they can do that without FDA regulation," he said, adding that the stipulation is whether they make claims of something being medical grade — "like a clinically appropriate, clinical grade blood pressure measurement" [s3]. He also indicated the agency would not act on isolated inaccuracies: "We're not going to go in there and say, 'There's one result that is inaccurate, [and] therefore we've got to shut this down'" [s3].

Devices claiming medical-grade status, or used to diagnose or treat specific conditions, remain subject to existing premarket requirements [s3].

What that means when you are reading a product page

The practical consequence for a consumer is that the presence or absence of a disclaimer now carries more information than it used to, and the presence or absence of validation carries less.

A device can estimate a physiologic parameter, display the number, and stay outside device regulation, provided it does not tell you what the number means clinically [s3]. Nothing in that arrangement requires the estimate to have been validated against a reference standard in a population resembling you, and nothing requires the accuracy to be published.

So the questions that separate a useful device from an expensive one are not answered on the box. Was the estimate compared against a clinical reference — a cuff, a blood draw, a neuropsychological assessment — and in whom? What is the error range on an individual reading, as opposed to a group average? Does the device report a trend, which is often robust, or a value, which often is not?

"Physiological age" is the clearest example of the problem. It is not a regulated term, it has no agreed reference method, and two products computing it from different inputs can return different numbers for the same person without either being wrong, because there is nothing to be wrong about.

The dementia case is the one to watch

Cognitive decline is the category where the gap between signal and claim is widest, and where the consequences of a false alarm are heaviest.

Samsung's feature works from walking patterns and voice [s1] — inputs chosen because they can be captured passively by hardware people already wear. Whatever the underlying signal turns out to be worth, a consumer device that flags a change is making a probabilistic statement about a population and delivering it to one person, with no confirmatory test attached and no clinical pathway behind it. Samsung's stated position is that the feature is not intended to diagnose medical conditions [s1].

There is a version of this that is genuinely valuable — continuous, passive data prompting an earlier clinical assessment that would otherwise have waited years. There is also a version that generates anxiety at scale in people who will never develop the condition. Which one arrives depends on evidence that has not yet been published.

What to watch

The signal worth following through 2026 is not the next product launch. It is whether any of these companies publishes validation data — accuracy against a clinical reference, in a defined population, with error bounds — now that the regulatory requirement to do so has loosened rather than tightened.

Sources

1. [s1] CES 2026 health tech products steal the spotlight at Las Vegas show. Fox News, 8 January 2026. https://www.foxnews.com/tech/10-health-tech-products-stealing-spotlight-ces-2026
2. [s2] CES 2026 shows AI becoming core to consumer health innovation. eMarketer, 5 January 2026. https://www.emarketer.com/content/ces-2026-shows-ai-becoming-core-consumer-health-innovation
3. [s3] FDA announces regulatory exemptions for 'non-medical grade' devices. Medical Device Network, 7 January 2026. https://www.medicaldevice-network.com/news/fda-announces-regulatory-exemptions-for-non-medical-grade-devices/